AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01973244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
Study NCT02457091 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
Study NCT00636727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthrocentesis
Description: Irrigate the TMJ with lactated ringers
Study NCT00636727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroscopy
Description: The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
Study NCT00636727 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: arthroplasty
Description: The disc will be surgically repositioned with open surgery
Study NCT06292052 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: Received neoadjuvant chemotherapy plus immunotherapy
Study NCT01710644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burlulipase
Description: Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
Study NCT01710644 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Caramel in sterile water)
Description: Placebo will be taken with meals and snacks for 5 to 7 days
Study NCT04510090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EP547
Description: EP547
Study NCT04510090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01566877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVI-7288
Description: Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV~The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day.
Study NCT01566877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline Solution (NSS)
Study NCT02748772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Two Anti-angiogenesis Drugs（Endostar and Thalidomide）
Description: Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Study NCT02748772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pure chemotherapy（Xelox）
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Study NCT02748772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pure chemotherapy（Xelox）
Description: CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.~Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
Study NCT00067080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670, deferoxamine
Study NCT02066571 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
Study NCT02066571 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sugar pill
Description: Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
Study NCT03647592 — intervention group
Intervention type: DRUG
Intervention: Erlotinib/Gefitinib combined with Bevacizumab
Description: Erlotlnib,150mg po qd/gefitinib 250mg po qd +Bevacizumab(15mg/kg),lvgtt,every 21 day ,evaluate every 2 months
Study NCT00122603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir
Description: ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
Study NCT00122603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir
Description: ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
Study NCT03251417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
Study NCT03251417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500 mg oral take, daily
Study NCT01860196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meditoxin
Study NCT01860196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Study NCT04546841 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: multipeptide cocktail
Description: Three groups of participant will be administered the multipeptide cocktail~1. Part I: Age 18-55 at the time of screening~2. Part II: Age 56-74 years at the time of screening~3. Part III: Age ≥ 75 years at the time of screening
Study NCT00460967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheopheresis
Description: 8 rheopheresis treatments over 10 wks.
Study NCT00460967 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Rheopheresis
Description: Sham treatment
Study NCT00687700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081
Description: GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
Study NCT00687700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK961081 matching placebo
Description: GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
Study NCT00687700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
Study NCT00687700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol matching placebo
Description: Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
Study NCT04315402 — intervention group
Intervention type: OTHER
Intervention: prospective, descriptive study via survey
Description: * Survey administered at check out.~* Patient's rate of follow-up data gathered via chart review.
Study NCT02164916 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: Given IV
Study NCT02164916 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT02164916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT02164916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT02164916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Given PO
Study NCT03413735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Green Tea Extract
Description: Confections containing green tea extract that will be ingested daily for 4 weeks
Study NCT03413735 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Confections containing no green tea extract that will be ingested daily for 4 weeks
Study NCT04501900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Study subjects diagnosed as stable, unstable ischemic coronary disease or myocardial infarction planning to undergo percutaneous coronary intervention (PCI) and no contradiction to prolonged DAPT are eligible for this trial. All subjects will provide written informed consent to participate. Subjects will be enrolled into the study before or within 24 hours after the index procedure. Subjects will be randomized to either discontinue P2Y12 inhibitor (clopidogrel or ticagrelor) (12 months total) or receive P2Y12 inhibitor for an additional 24 months (36 months total). Aspirin will be maintained in the entire study and can be replaced by cilostazol or indobufen if subjects are intolerant. Dosage of antiplatelet drugs will be according to local standard of practice. Subjects will be treated with XINSORB BRS only.
Study NCT00964782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will be randomized to receive Sildenafil first and then crossed over to receive the opposite intervention, placebo.
Study NCT00964782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive a look-alike placebo. Enrolled patients will be randomized to receive Placebo first and then crossed over to receive the opposite intervention, Sildenafil.
Study NCT00964782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil 2
Description: oral suspension, 0.5mg/kg, taken once prior to exercise stress test. Enrolled patients will receive Sildenafil, the crossed over intervention from their initial intervention (Placebo).
Study NCT00964782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Patient will receive a look-alike placebo. Enrolled patients will receive Placebo, the crossed over intervention from their initial intervention (Sildenafil).
Study NCT01922583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
Study NCT01010763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
Study NCT01010763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
Study NCT03789721 — intervention group
Intervention type: OTHER
Intervention: Medical Record Abstraction
Description: Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
Study NCT03789721 — intervention group
Intervention type: OTHER
Intervention: Biospecimen Sample Collection
Description: Collect research samples, when feasible for those diagnosed with ALD.
Study NCT03279458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linshom Respiratory Monitoring Device
Description: Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
Study NCT03279458 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Linshom Respiratory Monitoring Device
Description: Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
Study NCT01512888 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CL20-i4-EF1α-hγc-OPT
Description: Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
Study NCT01512888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given intravenously (IV).
Study NCT01512888 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs
Description: Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Drooling Impact Scale
Description: A scale with 10 items which are scored with visual analog scale from1 to 10. Drooling impact increases with increased scores.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Drooling Frequency and Severity Scale
Description: In this scale, parents or care givers were asked to rate the severity and frequency of drooling, classifying severity of drooling using a 5-level domain ranging from 1 (dry) to 5 (profuse drooling). The frequency of drooling was classified using a 4-level domain ranging from 1(no drooling) to 4 (constant drooling)
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD™)
Description: A quality of life scale that measure caregivers' perspectives on the health status, comfort, well being, and ease of caregiving of children with severe developmental disabilities. CPCHILD consists of 36 items distributed over six sections representing the following domains: (1) Personal Care (eight items); (2) Positioning, Transfer, and Mobility (eight items); (3) Communication and Social Interaction (seven items); (4) Comfort, Emotions, and Behaviour (nine items); (5) Health (three items); and (6) Overall Quality Of Life (one item). For the sections which involve the performance of skills, the degree of difficulty of accomplishing each task or activity was rated on a 7-point ordinal scale anchored by 0 ('No problem at all') to 6 ('Impossible').
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Drooling Quotient (DQ)
Description: DQ is a semi-quantitative method that assesses the presence of newly formed saliva on the lips every 15 seconds with 40 observations in 10 minutes, expressed as a percentage based on the ratio between the number of observed drooling episodes and the total number of observations.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Patient and caregiver visual analog scale (VAS) for drooling
Description: Patients will be asked to score their children's drooling severity on a visual analog scale (0-100 mm, 0 none to 100 severe)
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Functional Oral Intake Scale (FOIS)
Description: Functional Oral Intake Scale (FOIS) which is a 7-point ordinal scale document the functional level of oral intake of food and liquid.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: number of bibs daily used
Description: Parents will be asked their children's number of bibs daily used.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: number of hospital admissions per year related to respiratory infections
Description: Parents will be asked their children's number of hospital admissions per year related to respiratory infections.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Gross Motor Function Classification System (GMFCS)
Description: The GMFCS describes self-initiated movement and use of assistive devices (walkers, crutches, canes, wheelchairs) for mobility during an individual's usual activity.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Manual Ability Classification System (MACS)
Description: The MACS is also a simple, five-point ordinal classification system and was designed for use in children ages 4-18 years. The MACS is a validated measure in cerebral palsy that can be used to classify a child's typical use of both hands and upper limbs.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Communication Function Classification System (CFCS)
Description: The CFCS is a simple, five-point ordinal classification system that assesses everyday communication (not optimal communication) of children with cerebral palsy.
Study NCT04132765 — intervention group
Intervention type: OTHER
Intervention: Eating and Drinking Ability Classification System (EDACS)
Description: EDACS is a measure to assess eating and drinking ability for children with CP, ages 3 and older. This classification is a simple five-point ordinal system.
Study NCT06018090 — intervention group
Intervention type: OTHER
Intervention: The presence and rate of MES measured by TCD monitoring
Description: TCD monitoring within 24 hours from the last known well time. Bilateral M1 segments of middle cerebral artery were insonated at a single depth with 2-MHz transducers secured by a probe-holder.
Study NCT04224116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: to receive tranexamic acid (25mg/kg) in bolus at induction followed by 2mg/kg/h in continuous infusion until the end of the act.
Study NCT04224116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SSI
Description: Serum Salin isotonic injected
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: vitamin E (400 IU/day all rac-α-tocopheryl acetate)
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: selenium (200 μg/d L-selenomethionine)
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E placebo
Description: placebo
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E placebo
Description: placebo
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium placebo
Description: placebo
Study NCT00063453 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Selenium placebo
Description: placebo
Study NCT01502891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision Aid
Description: The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
Study NCT03955315 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IDCT
Description: Discogenic Cells + Sodium Hyaluronate Vehicle
Study NCT03955315 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Needle puncture under the muscular layer in front of the intervertebral disc
Study NCT02145390 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Bladder Tumor & Cystoscopy
Description: TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:~* Cystoscopic evaluation~* Bimanual examination under anesthesia,~* Transurethral resection of the bladder tumor,~* Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop.
Study NCT02145390 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:~* Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.~* Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.~* Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day~* Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume.
Study NCT02145390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expanded Prostate Cancer Index Composite Short Form 12
Description: Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
Study NCT02145390 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Score
Description: Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
Study NCT03820232 — intervention group
Intervention type: DEVICE
Intervention: temperature monitoring
Description: In every patient observed in this prospective observational study, body core temperature will be contemporaneously monitored through the oesophageal probe and the heated controlled servo sensor. Both are routinely used for this purpose in clinical practice
Study NCT04696198 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy Intervention
Description: Manual Therapy Interventions to improve range of motion and decrease pain
Study NCT04696198 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: standard care